Rituximab for the first-line treatment of stage III/IV follicular non-Hodgkin's lymphoma

Dundar Y, Bagust A, Hounsome J, McLeod C, Boland A, Davis H, Walley T, Dickson R
Record ID 32011001403
Authors' recommendations: On balance the evidence indicates that R-CVP is more cost-effective than CVP.
Project Status: Completed
Year Published: 2009
URL for published report: http://www.hta.ac.uk/1636
English language abstract: An English language summary is available
Publication Type: Not Assigned
Country: England, United Kingdom
MeSH Terms
  • Age Factors
  • Antibodies, Monoclonal, Murine-Derived
  • Disease-Free Survival
  • Male
  • Markov Chains
  • Middle Aged
  • Rituximab
  • Technology Assessment, Biomedical
  • Antibodies, Monoclonal
  • Antineoplastic Combined Chemotherapy Protocols
  • Cyclophosphamide
  • Lymphoma, Follicular
  • Prednisone
  • Vincristine
Organisation Name: NIHR Health Technology Assessment programme
Contact Address: NIHR Journals Library, National Institute for Health and Care Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science Park, Southampton SO16 7NS, UK
Contact Name: journals.library@nihr.ac.uk
Contact Email: journals.library@nihr.ac.uk
Copyright: 2009 Queen's Printer and Controller of HMSO
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.